Cantargia (Q4 Review): New Developments in PDAC - Redeye

Redeye comments on Cantargia's fourth quarter report 2025. We discuss the potentially changing treatment landscape after strong data from RAS inhibitors in pancreatic cancer. Cantargia is planning for a pivotal study in 2026, pending the finalisation of the IL1RAP diagnostic and funding. We believe this to be the main trigger for the share this year.

Länk till analysen i sin helhet: https://www.redeye.se/research/1153690/cantargia-q4-review-new-developments-in-pdac?utm_source=finwire&utm_medium=RSS